newsfilter
← Latest News
GlobeNewswire·

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the